The Impact of New Driver Mutations on Treatment of NSCLC

Video Library —June 15, 2021
Lauren Welch, MSN, NP-C, AOCNP
Nurse Practitioner
Tennessee Oncology
Nashville, TN
Lauren Welch, MSN, NP-C, AOCNP, discusses the impact that the discovery of new actionable molecular targets and oncogenic drivers has had on treatment of NSCLC, with at least 6 new targets, all with approved targeted therapies. She suggests that patients have better outcomes with targeted therapies upfront, so that identification of these targets early through broad NGS testing is essential in extending survival in patients with NSCLC.
Related Articles
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials.
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country